(Q39620425)

English

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.

scientific article published on 4 May 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV. (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

17

object named as

Jalid Sehouli

0 references

Martina Gropp-Meier

4

object named as

Martina Gropp-Meier

0 references

Barbara Schmalfeldt

10

object named as

Barbara Schmalfeldt

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

author name string

Werner Meier

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Andreas du Bois

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jörn Rau

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Klaus Baumann

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Jens Huober

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kerstin Wollschlaeger

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Rolf Kreienberg

8

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Ulrich Canzler

9

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Pauline Wimberger

11

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Barbara Richter

12

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Willibald Schröder

13

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Antje Belau

14

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Anne Stähle

15

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Alexander Burges

16

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

language of work or name

0 references

publication date

4 May 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

126

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

236-240

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Incorporation of bevacizumab in the primary treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Phase III Trial of Carboplatin Plus Paclitaxel With or Without Gemcitabine in First-Line Treatment of Epithelial Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer S

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Phase II study of carboplatin followed by sequential gemcitabine and paclitaxel as first-line treatment for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Triple cytotoxic therapy for advanced ovarian cancer: a failed application, not a failed strategy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Letter: Creatinine clearance: bedside estimate.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

A phase 3 trial of bevacizumab in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2012.04.050

7 January 2021

Identifiers

10.1016/J.YGYNO.2012.04.050

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39620425&oldid=1568159148"